Publications by authors named "J Pietzsch"
In this study, we investigated a novel anti-cancer drug design approach by revisiting diclofenac-based carborane-substituted prodrugs. The redesigned compounds combine the robust carborane scaffold with the oxindole framework, resulting in four carborane-derivatized oxindoles and a unique zwitterionic amidine featuring a nido-cluster. We tested the anti-cancer potential of these prodrugs against murine colon adenocarcinoma (MC38), human colorectal carcinoma (HCT116), and human colorectal adenocarcinoma (HT29).
View Article and Find Full Text PDFAims: Catheter-based radiofrequency renal denervation (RF RDN) is an interventional treatment for uncontrolled hypertension. This analysis explored the therapy's lifetime cost-effectiveness in a Canadian healthcare setting.
Materials And Methods: A decision-analytic Markov model was used to project health events, costs, and quality-adjusted life years over a lifetime horizon.
Article Synopsis
- Percutaneous transluminal angioplasty (PTA) for peripheral artery disease often results in vascular dissections, increasing the need for additional interventions (target lesion revascularization or TLR).
- A study using a decision-analytic model analyzed the clinical outcomes, costs, and quality of life impacts of using the Tack Endovascular System versus the standard PTA approach, showing lower TLR rates with the Tack-supported strategy.
- The results suggest that focal stenting (using Tack) is cost-effective for non-severe dissections and may even save costs for severe cases while improving patient quality of life, highlighting potential economic benefits in managing dissections post-PTA.
Background: The cost-effectiveness of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) has previously been reported across the spectrum of surgical mortality risk. We present an updated analysis specific to the UK based on 4-year data from the Evolut Low Risk Trial, which showed a maintained numerical survival benefit with TAVI.
View Article and Find Full Text PDFBackground: Catheter-based radiofrequency renal denervation (RF RDN) has recently been approved as an adjunctive treatment for hypertensive patients without adequate blood pressure control. This study assessed the cost-effectiveness of RF RDN in the United States based on contemporary clinical evidence.
Methods: A decision-analytic Markov model projected costs, quality-adjusted life years (QALY), and clinical events for an active cohort treated with RF RDN and a control cohort treated with standard-of-care (defined as 1, 2, or 3 antihypertensive medications).